{
    "ticker": "KRMD",
    "name": "Krystal Biotech, Inc.",
    "description": "Krystal Biotech, Inc. is a biotechnology company focused on developing innovative gene therapies for patients with rare diseases. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech is dedicated to transforming the treatment landscape for patients suffering from skin-related genetic disorders. The company\u2019s proprietary platform, Skin TAR, is designed to deliver gene therapy directly to the skin, enabling targeted treatments that address the root cause of genetic diseases. Krystal Biotech's lead product candidate, KB103, is in clinical trials for the treatment of dystrophic epidermolysis bullosa (DEB), a severe genetic skin disorder characterized by fragile skin that blisters easily. The company aims to leverage its technology to create a pipeline of therapies that can improve the quality of life for individuals affected by debilitating genetic conditions. Through its commitment to innovation and patient-centric solutions, Krystal Biotech strives to bring hope to families facing challenging health issues, making significant advancements in the field of dermatological gene therapy.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Pittsburgh, Pennsylvania, USA",
    "founded": "2015",
    "website": "https://www.krystalbiotech.com",
    "ceo": "Suma Krishnan",
    "social_media": {
        "twitter": "https://twitter.com/KrystalBiotech",
        "linkedin": "https://www.linkedin.com/company/krystal-biotech/"
    },
    "investor_relations": "https://investors.krystalbiotech.com",
    "key_executives": [
        {
            "name": "Suma Krishnan",
            "position": "CEO"
        },
        {
            "name": "Michele Garvey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "KB103"
            ]
        }
    ],
    "seo": {
        "meta_title": "Krystal Biotech, Inc. | Innovating Gene Therapies for Rare Diseases",
        "meta_description": "Krystal Biotech, Inc. focuses on developing gene therapies for rare skin diseases. Learn about their innovative solutions and commitment to patient care.",
        "keywords": [
            "Krystal Biotech",
            "Gene Therapy",
            "Dystrophic Epidermolysis Bullosa",
            "Rare Diseases",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What does Krystal Biotech specialize in?",
            "answer": "Krystal Biotech specializes in gene therapies for patients with rare skin diseases."
        },
        {
            "question": "What is KB103?",
            "answer": "KB103 is Krystal Biotech's lead product candidate for the treatment of dystrophic epidermolysis bullosa."
        },
        {
            "question": "Where is Krystal Biotech located?",
            "answer": "Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, USA."
        },
        {
            "question": "When was Krystal Biotech founded?",
            "answer": "Krystal Biotech was founded in 2015."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "SGMO",
        "AVTX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ABT",
        "BMY"
    ]
}